Oura Health, the $2.5 billion-valued sleep and health tracking company, filed for its U.S. initial public offering this week with a revenue composition that will surprise allocators who remember it as a direct-to-consumer ring seller. Insurance partnerships and corporate wellness programs now account for more than 40% of total revenue, according to analysis of the S-1 filing—a structural shift that repositions the company as a B2B2C health data platform with hardware as the wedge, not the endgame.

The filing shows Oura generated approximately $500 million in trailing twelve-month revenue as of the most recent quarter, with the enterprise and payor channel growing at roughly 80% year-over-year while pure DTC hardware sales expanded at 22%. The company's partnerships include unnamed U.S. health insurers offering subsidized rings to members, plus contracts with at least 200 employers providing devices through wellness benefit programs. Membership revenue—the $5.99 monthly subscription required to access Oura's health insights—contributed $180 million in the trailing period, representing recurring income that scales independently of hardware replacement cycles. The Finnish company sold approximately 2.1 million rings in the last fiscal year, but the filing makes clear that the unit with the higher lifetime value is the enterprise contract, not the individual consumer.

This matters because Oura is effectively arbitraging two different margin structures within one business model. Hardware gross margins sit near 48%, typical for premium wearables. But the insurance and employer partnerships deliver blended margins above 65% once subscription attachment and data licensing fees are included. Health insurers pay Oura both for subsidized hardware and for access to anonymized biometric trend data used in population health modeling—a dual revenue stream that consumer hardware companies rarely capture. The company's S-1 also discloses that 18% of enterprise users maintain their subscriptions even after leaving their employer or insurance plan, creating a organic DTC conversion funnel that costs Oura nearly zero in customer acquisition. The implication: Oura is building a health data moat by renting out its sensor network to payors, then keeping a fraction of those users as permanent retail customers. Allocators pricing this IPO need to decide whether they're valuing a $300 ring company with a subscription attach, or a health data infrastructure play that happens to manufacture its own sensor hardware.

The risk is that insurance partnerships are inherently less stable than they appear. Payor contracts typically run 24 to 36 months and are subject to renegotiation based on demonstrated health outcome improvements—metrics Oura must now report quarterly as a public company. The S-1 notes that two unnamed health insurance partners accounted for 23% of total revenue in the most recent quarter, creating a concentration problem if either contract is repriced or lost. Meanwhile, competitors are moving. Whoop recently signed its first payor partnership, and Apple continues to add clinical-grade health features that could eliminate the need for a dedicated sleep device if insurance companies decide the iPhone's sensors are sufficient. Oura's edge is its four-year dataset of nocturnal biometrics and a ring form factor with higher wear compliance than wrist devices, but that edge compresses the moment a major insurer decides to subsidize Apple Watches at scale.

Operators should watch for two follow-on signals in the next 90 to 120 days: first, whether Oura discloses the renewal rate on its largest payor contracts in the first earnings call post-IPO; second, whether any of the unnamed insurance partners go public with case studies showing cost savings or health improvements, which would validate the model and potentially trigger copycat deals across the industry. The company has indicated it will use IPO proceeds to expand its clinical research team and pursue FDA clearance for atrial fibrillation detection, which would open the door to Medicare reimbursement pathways.

The IPO is expected to price in late Q2 at a valuation near $3 billion, roughly 6x trailing revenue if the $500 million run rate holds. That multiple assumes the market believes the enterprise mix will reach 60% within two years.